⚠️ Research Use Only — Compounds discussed are research chemicals, not FDA-approved for human use. Not medical advice. Full disclaimers →
Also known as: FS-344
Follistatin-344 is a myostatin inhibitor research compound (not FDA-approved for human use) studied for muscle hypertrophy. Follistatin-344 is a naturally occurring protein studied for its ability to block myostatin, the body's built-in muscle growth limiter, enabling significantly enhanced muscle development. Research dose: 100–100 mcg 7x/wk. Half-life: 6 hours. Available from COA-verified vendors with code PEPTIDEX for up to 20% off.
Rankings independent · Research use only
Blocks myostatin (the body's muscle growth limiter) and activin, allowing enhanced muscle development and regeneration beyond normal physiological limits.
COA-verified vendors · Use code PEPTIDEX for up to 20% off
* Prices for research peptide acquisition. Not therapeutic products.
| Vendor | Purity | List Price | With PEPTIDEX | Code | Shop |
|---|---|---|---|---|---|
Bio Longevity LabsTriple-Tested | 99%+ | $499.0010 mg | $424.15Save 15% | PEPTIDEX | * Research vendor — verify your regional regulations before purchase. Shop |
Use code PEPTIDEX for 15% off at Bio Longevity Labs.
* Research vendor — verify your regional regulations before purchase.
Shop at Bio Longevity LabsBlocks myostatin (the body's muscle growth limiter) and activin, allowing enhanced muscle development and regeneration beyond normal physiological limits.
Rodino-Klapac et al. (Mol. Ther.): AAV-delivered follistatin 344 increases muscle mass and fiber diameter across multiple animal species without adverse reproductive or endocrine effects.
PreclinicalKalista et al.: Review of follistatin's role as primary endogenous myostatin antagonist and its therapeutic potential for muscular dystrophies and sarcopenia.
PreclinicalMendell et al. (Mol. Ther.): Phase I clinical trial of AAV1-follistatin gene transfer in Becker muscular dystrophy patients shows improved 6-minute walk test with no adverse effects.
ModerateResearch demonstrating follistatin's broader metabolic role in adipocyte browning, energy expenditure, and metabolic health beyond muscle hypertrophy.
PreclinicalA 2026 review found that while unapproved peptides like BPC-157 and TB-500 demonstrate favorable tissue repair in animal models, rigorous human safety data remain scarce. The researchers investigated the pharmacological mechanisms and regulatory status of these compounds in sports medicine.
EmergingIn a 2020 study, researchers demonstrated a compact, self-starting mode-locked thulium-doped fiber laser achieving a fundamental repetition rate of 344 MHz and a pulse duration of 160 fs. The system generated pulses centered at 1975 nm with a maximum output power of 560 mW.
EmergingHigh-dose subcutaneous injections of follistatin-344 were associated with the development of central serous chorioretinopathy in eleven bodybuilding athletes, according to a 2020 retrospective case series. The study demonstrated that symptoms and subretinal fluid generally resolved after discontinuing the peptide.
ModerateA 2019 study demonstrated that only nine of 17 tested black market follistatin 344 products actually contained the peptide. Researchers successfully developed an electrophoretic detection method to identify these His-tagged illicit peptides in serum and urine.
PreclinicalA 2017 study demonstrated that transgenic expression of human follistatin-344 in pigs significantly increased skeletal muscle mass and reduced body fat. Researchers found this growth was driven by myofiber hypertrophy and altered signaling pathways, without causing cardiac or reproductive abnormalities.
PreclinicalResearch-only. Potent effects potential for unregulated growth. Limited human safety data. Phase I gene therapy trials show safety.
See our evidence grading methodology for how we evaluate and grade peptide safety data.
* Dosing data from published literature — not a human use recommendation.
Very short cycles. 100mcg/day common. Acts via myostatin/activin inhibition effects compound over days.
Last updated: 2026-01 · Laws change frequently. Verify current status in your jurisdiction.
Weeks 2–4
Initial myostatin inhibition; muscle fullness and pumps
Month 2–3
Measurable lean mass increase; strength gains
Long-term
Very limited long-term human data; Phase I gene therapy shows safety
| Side Effect | Incidence | Severity |
|---|---|---|
Limited human safety data | Investigational only | mild |
Injection site reaction | ~5% of users | mild |
Theoretical cancer promotion Myostatin inhibition could allow unregulated cell growth | Mechanism-based concern | rare |
Finding verified, high-purity Follistatin-344 requires rigorous COA verification. We independently evaluate vendors based on third-party HPLC testing, purity thresholds (≥98%), and batch-specific documentation.
View COA-Verified Follistatin-344✓ Third-party tested·✓ US shipping·✓ COA on every batch
Disclosure: PeptiDex may earn a commission from purchases made through affiliate links. This does not affect our editorial independence or recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
⚠️ Educational only · Not medical advice · For research use only. Information on this page is compiled from peer-reviewed literature and is intended strictly for educational and informational purposes. Peptides discussed may be unapproved research chemicals — consult a licensed healthcare professional before considering any peptide compound. Read our full disclaimer
Affiliate disclosure: PeptiDex may earn commissions from purchases made through vendor links on this page. This does not affect our editorial ranking or vendor recommendations — we exclusively feature vendors that pass independent COA verification. See our methodology · Editorial policy
12stacks • exact dosages • cycle lengths • printable reference
No spam. Unsubscribe anytime.
Independent researcher, not a medical professional
PeptiDex Research is the byline used by the independent researcher who builds and maintains PeptiDex. The site is a one-person research project — there is no editorial board, no medical reviewers, and no clinical staff. Content is produced by reading...
View profile